Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intensive glucose lowering has previously been shown to increase mortality among persons with advanced type 2 diabetes and a high risk of cardiovascular disease. This report describes the 5-year outcomes of a mean of 3.7 years of intensive glucose lowering on mortality and key cardiovascular events. METHODS: We randomly assigned participants with type 2 diabetes and cardiovascular disease or additional cardiovascular risk factors to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level of 7 to 7.9%). After termination of the intensive therapy, due to higher mortality in the intensive-therapy group, the target glycated hemoglobin level was 7 to 7.9% for all participants, who were followed until the planned end of the trial. RESULTS: Before the intensive therapy was terminated, the intensive-therapy group did not differ significantly from the standard-therapy group in the rate of the primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) (P=0.13) but had more deaths from any cause (primarily cardiovascular) (hazard ratio, 1.21; 95% confidence interval [CI], 1.02 to 1.44) and fewer nonfatal myocardial infarctions (hazard ratio, 0.79; 95% CI, 0.66 to 0.95). These trends persisted during the entire follow-up period (hazard ratio for death, 1.19; 95% CI, 1.03 to 1.38; and hazard ratio for nonfatal myocardial infarction, 0.82; 95% CI, 0.70 to 0.96). After the intensive intervention was terminated, the median glycated hemoglobin level in the intensive-therapy group rose from 6.4% to 7.2%, and the use of glucose-lowering medications and rates of severe hypoglycemia and other adverse events were similar in the two groups. CONCLUSIONS: As compared with standard therapy, the use of intensive therapy for 3.7 years to target a glycated hemoglobin level below 6% reduced 5-year nonfatal myocardial infarctions but increased 5-year mortality. Such a strategy cannot be recommended for high-risk patients with advanced type 2 diabetes. (Funded by the National Heart, Lung and Blood Institute; ClinicalTrials.gov number, NCT00000620.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those levels predict the risk of cardiovascular disease.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Diabetic kidney disease might also play a role in the arrhythmia-associated mechanism of sudden death in this setting.655”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [655]
Experimental — accuracy not yet measuredIn the citing paper
“However, the belief that HbA1c was a surrogate marker was contradicted by findings from the ACCORD trial that diabetics randomly assigned to intensive treatment that reduced HbA1c levels in fact increased the risk of CVD events [14].”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“For example, intensive hypoglycemic treatments, such as oral hypoglycemics and insulin, substantially reduce fasting glucose and HbA1c levels.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“Similar U-shaped curves were found in a 7-year observational study of persons with T1D and a 22-year observational study of >20,000 persons with T2D.83,84”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citationEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Self-citationGlycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Huxley, R., Barzi, F., & Woodward, M. (2006) · BMJ · doi:10.1136/bmj.38678.389583.7c · Cited by 1,534
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Miller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429
Cited by
Items 901–1,000 of 1,000
Isaza, D., Gómez, M. Z., & Gómez, J. R. M. (2013) · Medicina UPB · Cited by 2
A survey of corticosteroid use for the management of septic shock
Govender, K., & Rodseth, R. N. (2012) · Southern African Journal of Anaesthesia and Analgesia · doi:10.1080/22201173.2012.10872853
Huang, F., & Chen, M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.10.202
“5 reduced the risk of cardiovascular outcomes among diabetic patients is supported by some randomized controlled trials [1] but not all trials [2].”
BackgroundIntensive glucose lowering (HbA1c target<6.0%) for people with type 2 diabetes increases mortality
Shaw, J. E. (2011) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2011-100035
Sekundärprophylaxe des Schlaganfalls aus neurologischer Perspektive
Seidel, G. (2013) · Herz · doi:10.1007/s00059-013-3774-6
Primary prevention of coronary artery disease in patients with type 2 diabetes mellitus
Harrall, J. M., & Tufo, A. (2012)
EXAMINE: targeting risk and treatment in diabetes
Hülsmann, M., Pacher, R., & Neuhold, S. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00407-9
Kalain, A. (2014) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Diabetes and Coronary Artery Disease
Sethi, S. S., & Farkouh, M. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-20415-4_4
Management of the older person with diabetes mellitus
Oba, K. (2012) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.49.561
Reborn the Controversy Related with the use of Sulfonylureas
Zárate, A. (2014) · Journal of Endocrinology and Diabetes · doi:10.15226/2374-6890/1/2/00109
“Some of the newer diabetes drugs have been associated with heart failure [6-9]; moreover, a recent report from the Clinical Practice Research Datalink in United Kingdom which was presented at the annual meeting of the European Association for the study of Diabetes in 2013, analyzed patients with type 2 diabetes using…”
BackgroundDiabetes care: some improvements, more challenges, some opportunities!
Hh, T., & Sum, C. F. (2013) · Singapore Medical Journal · doi:10.11622/smedj.2013133
2. Therapeutic Strategy for Diabetic Nephropathy.
Koya, D. (2011) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.100.2592
More Follow-Up from the ACCORD Trial
Brett, A. S. (2011) · Journal watch · doi:10.1056/jw201103020000001
Effects of Cardiotonic Steroids and Insulin on Sodium Pump Signaling
Gupta, S. (2014) · OhioLink ETD Center (Ohio Library and Information Network)
Dose d’insuline et mortalité cardiovasculaire : nouvelles données de l’étude ACCORD
Mohammedi, K. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30079-7
Understanding insulin management: Role of the
Haines, S. T. (2014)
Evaluation and Management of the Newly Diagnosed Patient with Type-2 Diabetes
Miller, J. D. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2059-4_42
Recommendations for management of high renal risk chronic kidney disease
Ferro, C. J., & Ng, K. P. (2015) · Oxford University Press eBooks · doi:10.1093/med/9780199592548.003.0099
Sluik, D. (2012) · DepositOnce · doi:10.14279/depositonce-3267
“3) Food group intake, g/d Potatoes 85 [60-116] 102 [70-134] 74 [49-91] 83 [57-112] 99 [77-133] Vegetables 157 [129-192] 158 [130-194] 157 [129-191] 159 [132-195] 142 [114-171] Legumes 3 [0-7] 3 [0-7] 3 [0-6] 3 [0-7] 1 [0-5] Fruit 193 [133-281] 175 [116-274] 209 [153-284] 198 [137-287] 158 [111-221] Nuts and seeds 1 [0…”
“If the Facts Don’t Fit the Theory, Change the Theory”: Implications for Health System Reform
Sturmberg, J. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-26221-5_21
Hansel, B. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30194-2
Mannucci, E., & Perriello, G. (2012)
岡畑, 純., 浩二郎, 植., 輝男, 柴., & 孝, 門. (2011) · 糖尿病 · doi:10.11213/tonyobyo.54.880
Lange, R. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-4815-0.00016-7
Managing the Information Boundary of an Organization
Krumholz, H. M., & Downing, N. S. (2014) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.114.001500
Langfristige Effekte einer multifaktoriellen Therapie bei Typ-2-Diabetes
Jecht, M. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0156-8
Should the Target A1C Level Be Less Than 7 Percent
Barry, H. C. (2012)
Jiang, H., Wang, Y.-H., Wei, C., Zhang, X., Liu, H.-C., & Liu, X. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.129
Kardiovaskuläre Aspekte der Diabetestherapie: Endlich Grund zur Freude für Kardiologen
Forst, T. M., Plum‐Mörschel, L., & Weber, M. M. (2017) · Der Internist · doi:10.1007/s00108-017-0189-0
“1 Übersicht klassischer Endpunktstudien zur Evaluation der Überlegenheit einer Intervention oder spezifischer Pharmaka UKPDS 33 [31] ACCORD [10] VADT [5] ADVANCE [26] Steno 2 [7] PROactive [3] ORIGIN N 4620 10.251 1792 11.140 160 5238 12.612 Alter (Jahre) 53 62 60 66 55 62 64 Diabetesdauer (Jahre) 0 10 11,5 8 6,0 8 5…”
BackgroundInfluentialArao, T., Okada, Y., Torimoto, K., Sugai, K., Otsuka, T., Kurozumi, A., & Tanaka, Y. (2017) · Journal of UOEH · doi:10.7888/juoeh.39.1
Glycemic Control and Diabetes Macroangiopathy
Bordier, L., & Bauduceau, B. (2017) · International Journal of Medicine and Surgery · doi:10.15342/ijms.v4is.136
Impacto cardiovascular de la hipoglicemia
Espitia, M. D. L. (2017) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2016.12.002 · Cited by 2
Evaluation of Protein Glycation and Antioxidant Levels in Birds of Prey
Ingram, T. D. (2017)
Seufert, J., Galle, J.-C., Manning, M., Schmid, V., & Lehrke, M. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-112658
“[17] Gerstein HC, Miller ME, Genuth S et al.”
BackgroundThe accumulation of advanced glycation endproducts in diabetes and its relation to vascular disease
van Eupen (2017) · Research Publications (Maastricht University) · doi:10.26481/dis.20170907mve
Screening and Basic Workup of a Patient with Peripheral Vascular Disease – A Primer of Physicians
Kolman, S. E., Placido, J., Patel, A. J., & Rm, G. (2017) · Journal of Clinical and Experimental Research in Cardiology · doi:10.15744/2394-6504.3.202
Packer, M. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.03.006
Kosteneffektivität einer individualisierten Diabetestherapie
Pavlicek, V. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0326-y
“In der ACCORD-Studie (ACCORD: „action to control cardiavascular risk in diabetes“) zeigte sich, dass bei Patienten, welche ein hohes kardiovaskuläres Risiko haben, eine zu intensive glykämische Kontrolle mit einer gesteigerten Mortalität einhergeht [2].”
BackgroundDiabetologie: Ein orales Antidiabetikum, das die Mortalität verringert
Maitre, S., Portela, M., & Philippé, J. (2015) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2015.02513
What Should the Hemoglobin A1c Level Goal be in Diabetics?
Aronow, W. S. (2015) · International Journal of Diabetology & Vascular Disease Research · doi:10.19070/2328-353x-1500029 · Cited by 1
Erkrankungen des Stoffwechsels ∗ ∗Überarbeitet und aktualisiert von Dr. Walter Burghardt
Kasper, H. (2014) · Elsevier eBooks · doi:10.1016/b978-3-437-42013-9.00004-x
Ismail, M., Ibrahim, A. S. A., & Gamal, A. M. (2018) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000802
Houston, M. C. (2018) · CRC Press eBooks · doi:10.1201/9781315121024-11
Maleki, M., & Hosseini, Z. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-51149-0.00016-x
What caused this transient or persisting ischemic event?
Testai, F. D. (2019) · Wiley eBooks · doi:10.1002/9781118492390.ch6 · Cited by 2
GLYCAEMIA SELF-CONTROL ROLE IN PREVENTION OF CARDIOVASCULAR DISEASES IN DIABETES MELLITUS PATIENTS
Shatskaya, O. A., & Kukharenko, S. S. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-11-166-169
O’Connor, P. J., Sperl‐Hillen, J. M., & Gilmer, T. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_22
Houston, M. C. (2019) · Alternative and Complementary Therapies · doi:10.1089/act.2019.29233.mho
The role of venous return in organ perfusion
van Loon, L. M. (2019) · doi:10.3990/1.9789036549462
Revolutionary New Concepts in the Prevention and Treatment of Cardiovascular Disease
Houston, M. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-30730-1_47
Lange, R. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-47870-0.00015-5
Kardiovaskuläre Effekte von GLP-1-Rezeptoragonisten
Kahles, F., & Lehrke, M. (2020) · Diabetes aktuell · doi:10.1055/a-1152-2125
Impact of continuous glucose monitoring with diabetic education on glycemic variability and HbA1c
Varughese, M., Mathew, R., Varghese, J., Chacko, C. A., & Augustine, D. V. (2020) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20203038
Actual analysis of modern therapeutical aspects in HTA treatment and associated comorbidities
Universitatea de Medicină şi Farmacie „Carol Davila“, B., Bejan, G. C., Stănescu, A. M. A., Universitatea de Medicină şi Farmacie „Carol Davila“, B., Ghilencea, L. N., Universitatea de Medicină şi Farmacie „Carol Davila“, B., Matei, D. B., & Universitatea de Medicină şi Farmacie „Carol Davila“, B. (2018) · Romanian Medical Journal · doi:10.37897/rmj.2018.2.5 · Cited by 6
“Tratamentul antidiabetic oral se va face de pri-m ă inten ţ ie cu metformin, dac ă nu exist ă contrain-dica ţ ii, care face parte din clasa biguanide – cu efect pe sc ă derea rezisten ţ ei la insulin ă pentru atin-gerea ţ intei terapeutice în cazul HbA1c de sub 7% (30).”
Cardiodiabetology: Reducing Risks to Optimize Cardiovascular Disease Outcomes
Wong, N. D., & Handelsman, Y. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_12 · Cited by 1
de Vries, T. I. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/352
Liu, L., Luo, H., Shu, Y., Liang, Y., & Tang, J.-L. (2021) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-00946-4 · Cited by 1
Sharma, M., Das, M., Sarma, J., & Alam, S. (2021) · The Indian Journal of Nutrition and Dietetics · doi:10.21048/ijnd.2021.58.2.26727
Hatziisaak, N. B., Hatziisaak, T., & Keller, U. (2021) · Russian Open Medical Journal · doi:10.15275/rusomj.2021.0207
“However, the ACCORD study showed that “the lower the better” was not suitable in the treatment of T2DM, as lower HbA1c levels were correlated to higher mortality [2].”
BackgroundFu, L., Tai, S., Sun, J., Zhang, N., Zhou, Y., Xing, Z., Wang, Y., & Zhou, S. (2021) · Research Square · doi:10.21203/rs.3.rs-960363/v1
Olika terapiers påverkan på riskfaktorena för hjärt-och kärlsjukdomar hos diabetespatienter
Westerberg, H. T. (2014)
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/review2
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v2/decision1
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/decision1
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/review3
Reifsnider, O. S., Pimple, P. M., Brand, S. B., Washington, E. B., Shetty, S. S., & Desai, N. R. (2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v2/response1
Akutes Koronarsyndrom: Wie geht es nach der Akutphase weiter?
Mause, S. F., & Marx, N. (2016) · Deutsches Ärzteblatt · doi:10.3238/perskardio.2016.10.14.01
Individualisierte Behandlung: Jeder Diabetiker hat sein persönliches Therapieziel
Nauck, M. A. (2015) · Deutsches Ärzteblatt · doi:10.3238/persdia.2015.04.24.04
Pandya, N., & Patel, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-01782-8_38-1
(2011) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328348da50
Type 2 diabetes: glycaemic control
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch10
Evolving Type 2 diabetes management focuses on clinical outcomes
Fenton, C., & Kang, C. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00903-z
“ACCORD trial shows intense glycaemic control is harmful in some pts [12] Focus modified to avoid ↑ weight, hypoglycaemia, HF and ADEs Ultra-long acting insulin (degludec)”
BackgroundPrevention and management of cardiovascular disease in kidney disease and kidney failure
Garimella, P. S., Weiner, D. E., & Sarnak, M. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818540-7.00020-3
Metabolic syndrome, hyperglycemia, and type 2 diabetes
Opie, L. H., & Meier, J. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-3322-4.00020-x
Nutrition, Chronic Kidney Disease, and Kidney Failure
Heber, D., & Li, Z. (2017) · CRC Press eBooks · doi:10.1201/9781315152165-12
Quantifying Treatment Effects Using Randomized Trials
Newman, T. B., & Kohn, M. A. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108500111.009
The Treatment of Diabetes after an Acute Ischaemic Stroke
Biessels, G. J. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2012.08.02.75
Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Schinner, S. (2011) · Yearbook of Endocrinology · doi:10.1016/j.yend.2011.06.008
Clinical and metabolic features of diabetic encephalopathy
Иванович, Г. В., Privalova, M. A., Garan, T. A., & Гулак, Д. А. (2022) · HERALD of North-Western State Medical University named after I I Mechnikov · doi:10.17816/mechnikov108788
Monami, M. (2022) · il Diabete · doi:10.30682/ildia2203d
Hu, F., Miao, X., Lv, X., Ren, L., Yang, F., Liu, Q., Lu, Y., Gong, Y., Yan, S., Tian, H., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2533512/v1
Eriş, D. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2576
Tight Control of Diabetes in Adult Patients (ACCORD)-2008
Carvajal, J., & Palko, G. (2023) · Springer eBooks · doi:10.1007/978-3-031-25620-2_19
O’Connor, P. J., Vickery, K. D., & Gilmer, T. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_24
Lima, G. G. D. C., Caldas, L. P. D. S., Krohling, K. R., de Carvalho, L. P. F., Franco, G. F., Silva, A. G. D. S. E., Duda, T. M. B., Oliveira, P. M. R. E., Gomes, L. S., & Mota, L. P. (2023) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v9i8.10967
Mohamed, E. M., Kareem, H., Zahran, S. M., & Sissy, M. H. E. (2021) · The Egyptian Journal of Laboratory Medicine · doi:10.4103/ejolm.ejolm_4_22
Fueling fate: Metabolic crosstalk in the bone marrow microenvironment
Lisi-Vega, L. E., & Méndez‐Ferrer, S. (2023) · Advances in stem cells and their niches · doi:10.1016/bs.asn.2023.08.001
Yang, G. (2024) · Frontiers research topics · doi:10.3389/978-2-8325-5476-0
Detection and Treatment of Chronic Complications
Soe, K. K., & Gunasekaran, U. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch05
Ghani, N. A., Hassan, S. N. F. S., Abidin, R. Z., Zakaria, Z., Nasir, F., & Azmi, A. Z. (2025) · Journal of Pharmacy · doi:10.31436/jop.v5i1.331
Schmaling, K. B., & Kaplan, R. M. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009391733.013
Schmaling, K. B., & Kaplan, R. M. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009391733.006
Metadata
- Authors
- The ACCORD Study Group
- Affiliations
- McMaster University (CA)
- Corresponding author
- The ACCORD Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-03-03
- Volume
- 364
- Issue
- 9
- Pages
- 818-828
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4083508
- OpenAlex
- W2125468958
- Cited by
- 1,035
- References
- 18
- Citations by year
- 2026: 12 · 2025: 33 · 2024: 27 · 2023: 35 · 2022: 29 · 2021: 61 · 2020: 51 · 2019: 53 · 2018: 81 · 2017: 78 · 2016: 80 · 2015: 91 · 2014: 100 · 2013: 108 · 2012: 120
- FWCI
- 104.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, Y1-HC-9035, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, N01 HC095180, Y01 HC009035, Y1-HC-1010, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, HbA1c, cardiovascular outcomes, mortality, myocardial infarction, stroke, cardiovascular disease, glycemic targets, hypoglycemia, adverse events, long-term follow-up, EXSCEL trial
- MeSH terms
- Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Proportional Hazards Models, Treatment Outcome, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.